Argenx Se (ARGX) Long-Term Investments (2015 - 2025)
Argenx Se's (ARGX) quarterly Long-Term Investments came in at $3.4 million in Q4 2025, down 63.55% YoY from $9.3 million in Q4 2024, and down 99.97% on a QoQ basis from $10.7 billion in Q2 2025.
Argenx Se (ARGX) Long-Term Investments (2015 - 2025) Analysis & Trends
Argenx Se (ARGX) has 11 years of Long-Term Investments data on file, last reported at $3.4 million in Q4 2025.
- Quarterly Long-Term Investments fell 63.55% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (down 63.55% YoY) and the FY2025 annual result came in at -$6.5 million, down 170.13% from the prior year.
- Long-Term Investments fell to $3.4 million in Q4 2025, from $10.7 billion in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $10.7 billion in Q2 2025 to a low of -$370.3 million in Q2 2021.
- A 5-year average of $1.0 billion and a median of $7.9 million in 2024 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2021 — Long-Term Investments slumped 223.7% — and 2025, when it jumped 161757.86%.
- Tracing ARGX's Long-Term Investments over 5 years: stood at $76.7 million in 2021, then slumped by 98.27% to $1.3 million in 2022, then jumped by 649.21% to $9.9 million in 2023, then slipped by 6.5% to $9.3 million in 2024, then tumbled by 63.55% to $3.4 million in 2025.
- The last three Long-Term Investments figures came in at $3.4 million (Q4 2025), $10.7 billion (Q2 2025), and $9.3 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.38 Mn |
| Jun 30, 2025 | 10.68 Bn |
| Dec 31, 2024 | 9.27 Mn |
| Jun 30, 2024 | 6.60 Mn |
| Dec 31, 2023 | 9.91 Mn |
| Jun 30, 2023 | 12.44 Mn |
| Dec 31, 2022 | 1.32 Mn |
| Jun 30, 2022 | -234.24 Mn |
| Dec 31, 2021 | 76.66 Mn |
| Jun 30, 2021 | -370.34 Mn |
| Dec 31, 2020 | 6.13 Mn |
| Jun 30, 2020 | 299.38 Mn |
| Dec 31, 2019 | 2.87 Mn |
| Jun 30, 2019 | -548.94 Mn |
| Mar 31, 2019 | 23.87 Mn |
| Dec 31, 2018 | 1,141.40 |
| Jun 30, 2018 | -34.70 Mn |
| Dec 31, 2017 | 1,177.43 |
| Jun 30, 2017 | -100.13 Mn |
| Dec 31, 2016 | 1,079.72 |